Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in biological products with a current market capitalization of just $5.92 million, announced on Thursday that it has received a ...

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in biological products with a current market capitalization of just $5.92 million, announced on Thursday that it has received a ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

(RTTNews) - Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel disease, on Monday announced the appointment of Norman ...

Mr. Staskey has worked for Danforth Advisors since 2021, working as Chief Financial Officer for clients such as Azitra, Inc., a biotechnology company developing novel dermatology therapeutic ...

Shares of NASDAQ ONVO opened at $0.37 on Friday. Organovo has a 12 month low of $0.32 and a 12 month high of $1.74. The company has a market cap of $5.69 million, a price-to-earnings ratio of -0. ...

Organovo is a clinical stage biotechnology company that is developing drugs that are demonstrated to be effective in three-dimensional (3D) human tissues as candidates for drug development.